Latest news for Broncus Holding (OTC:BRNHF) Stock

Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.

Broncus Holding Corp

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Wood Lay initiated coverage on FirstSun Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSUN#NASDAQ">FSUN</a>) with an Outperform rating and announced a price target of $46. Firstsun Capital shares closed at $39.49 on Friday. <a href="https://www.benzinga.com/quote/fsun/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>China Renaissance analyst Colin Liu initiated coverage on MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy rating and announced a price target of $351. MongoDB shares closed at $253.11 on Friday. <a href="https://www.benzinga.com/quote/msb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Jason Gursky initiated coverage on Curtiss-Wright Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Buy rating and announced a price target of $410. Curtiss-Wright shares closed at $366.92 on Friday. <a href="https://www.benzinga.com/quote/cw/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Priya Sachdeva initiated coverage on Penumbra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy rating and announced a price target of $305. Penumbra shares closed at $263.69 on Friday. <a href="https://www.benzinga.com/quote/pen/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Jason Gursky initiated coverage on V2X, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) with a Buy rating and announced a price target of $64. V2X shares closed at $52.93 on Friday. <a href="https://www.benzinga.com/quote/vvx/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MDB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072846/image-135-1024x494.png" alt="" class="wp-image-742334" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072846/image-135-1024x494.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072846/image-135-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072846/image-135-768x370.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21072846/image-135.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43091705/top-4-health-care-stocks-you-may-want-to-dump-in-q1">Top 4 Health Care Stocks You May Want To Dump In Q1</a></li>
</ul>

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

FSUN

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and maintains $15 price target.

Price Target

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target

Morgan Stanley analyst John Glass maintains Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) with a Equal-Weight and lowers the price target from $82 to $79.

Morgan Stanley Maintains Equal-Weight on Sysco, Lowers Price Target to $79

<h2><a href="https://www.jnj.com/media-center/press-releases/european-commission-approves-lazcluze-lazertinib-in-combination-with-rybrevant-amivantamab-for-the-first-line-treatment-of-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer">https://www.jnj.com/media-center/press-releases/european-commission-approves-lazcluze-lazertinib-in-combination-with-rybrevant-amivantamab-for-the-first-line-treatment-of-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer</a></h2>
&nbsp;
<h2>&nbsp;</h2>
<h2>Latest topline data from the Phase 3 MARIPOSA study shows amivantamab plus lazertinib is the first regimen to demonstrate superior overall survival benefit compared to the current standard of care osimertinib1 Median overall survival improvement is expected to exceed one year1</h2>

Biotech

Global

General

European Commission Approves LAZCLUZE In Combination With RYBREVANT For The first-Line Treatment Of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Morgan Stanley analyst Brian Harbour maintains Performance Food Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) with a Equal-Weight and raises the price target from $94 to $96.

PFGC

Morgan Stanley Maintains Equal-Weight on Performance Food Gr, Raises Price Target to $96

Wells Fargo analyst Jared Shaw upgrades Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) from Underweight to Equal-Weight and raises the price target from $40 to $48.

Upgrades

Wells Fargo Upgrades Bank OZK to Equal-Weight, Raises Price Target to $48

Needham analyst Joshua Reilly reiterates AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) with a Buy and maintains $25 price target.

Reiteration

AEYE

Needham Reiterates Buy on AudioEye, Maintains $25 Price Target

Chinese smartphone maker Xiaomi&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) first EV — the SU7 — outsold American EV giant Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Model 3 sedan in China in December.
What Happened: Xiaomi chairman Lei Jun noted the achievement in a post on the social media platform Weibo.
While 25,815 Xiaomi SU7 vehicles were sold in December, only 21,046 Model 3s were sold. The best-selling EV in the month, however, was BYD Co.&#8217;s Seagull, of which the company sold 48,754 units.
Xiaomi launched its first EV — the SU7 sedan — in late March and started delivering the vehicles in April. 
The SU7 is available in three variants, namely Standard, Pro, and Max with the lower-end variant starting at 215,900 yuan ($29,500), lower than Tesla&#8217;s cheapest offering — the Model 3 — in China.
Why It Matters: Tesla hiked the price of the Model 3 in China earlier this month by 3,600 yuan. The vehicle now starts at 235,500 yuan in the country with the higher-end Performance variant priced at 339,500 yuan.
Tesla also launched a refreshed Model Y in China this month. The refreshed vehicle starts at&nbsp;<a href="https://www.benzinga.com/tech/25/01/42905406/tesla-launches-refreshed-model-y-in-china-amid-rising-competition" target="_blank" rel="noreferrer noopener">263,500 yuan on Tesla&#8217;s website</a>, nearly 5.4% pricier than the older version of the vehicle which started at 249,900 yuan.&nbsp;
China is an important market for Tesla. In 2024, the company reportedly&nbsp;<a href="https://www.benzinga.com/25/01/42782683/tesla-hits-record-ev-sales-in-china-despite-global-dip" target="_blank" rel="noreferrer noopener">sold around 657,000 vehicles in China</a>, marking a growth of 8.8% year-on-year, even while its global annual deliveries fell as compared to 2023.
Tesla reported global&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on" target="_blank" rel="noreferrer noopener">deliveries of 1.79 million</a>&nbsp;vehicles in 2024, down from full-year deliveries of 1.81 million in 2023, marking the first decline in over a decade.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43090016/which-evs-might-lose-7500-ev-tax-credit-under-trump-administration" target="_blank" rel="noreferrer noopener">Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

XIACF

Tesla Model 3 Loses To Xiaomi SU7 In China's December Sales Showdown

Management

BIRK

Birkenstock Group Appoints Ivica Krolo As Finance Chief Effective February 1, 2025

Successfully treated atrial fibrillation (AF) in initial 30 patients with the Nanosecond PFA 360° Cardiac Catheter
Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation&#x2122; (nsPFA&#x2122;) technology, today announced the late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study, which data were recently presented at the 30th Annual AF Symposium 2025 meeting.
The feasibility study is intended to assess the initial safety and efficacy of the Nanosecond PFA 360° Cardiac Catheter System for the treatment of AF (NCT06696170). To date, 77 patients have been treated by six investigators, including Dr. Vivek Reddy and Prof. Petr Neuzil, in cases performed at Na Holmolce Hospital in Prague and Dr. Johan Vijgen at Jessa Hospital in Hasselt. The initial cohort of the first 30 patients treated have been evaluated by remapping completed at ~3 months post ablation procedure.

PLSE

Pulse Biosciences Announces Nanosecond PFA 360° Cardiac Catheter Study Results, 92.4% Success At 3 Months In Initial 30 AF Patients; IDE Study Planned For 2025

Morgan Stanley analyst Brian Harbour maintains Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) with a Equal-Weight and lowers the price target from $15 to $13.

PTLO

Morgan Stanley Maintains Equal-Weight on Portillos, Lowers Price Target to $13

WIIM

HSDT

Helius Medical Technologies shares are trading higher after the company announced it exceeded its initial enrollment target for its stroke pivotal study.

Needham analyst Joshua Reilly reiterates Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) with a Buy and maintains $25 price target.

JAMF

Needham Reiterates Buy on Jamf Holding, Maintains $25 Price Target

Guidance

BLRX

BioLineRx Outlines Vision For 2025: Plans New Oncology/Rare Disease In-Licensing, 1-For-40 Reverse Stock Split To Meet Nasdaq Compliance, $29.5M Cash, Runway Through H2 2026

Morgan Stanley analyst Brian Harbour maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Overweight and lowers the price target from $510 to $496.

Morgan Stanley Maintains Overweight on Domino's Pizza, Lowers Price Target to $496

UPDATE: Canaan Boosts December Mining to 62 BTC, Projects FY25 Revenue Of $900M-$1.1B

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy and maintains $44 price target.

SMMT

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target

Mesa Air Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) ("Mesa" or the "Company") today announced that it received a notice ("Notice") on January 15, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") because the Company failed to timely file its Annual Report on Form 10-K for the fiscal year ended September 30, 2024 (the "Form 10-K") with the Securities and Exchange Commission. The filing delay is not the result of a forthcoming restatement of the Company's financial statements or any disagreement with the Company's auditors.

MESA

Mesa Air Group Receives Non Compliance Notice From Nasdaq

Morgan Stanley analyst John Glass maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Equal-Weight and lowers the price target from $53 to $45.

JACK

Morgan Stanley Maintains Equal-Weight on Jack In The Box, Lowers Price Target to $45

Existing mining operations, constituting the first 400 MW Phase I development at the Corsicana Facility and Riot's Rockdale and Kentucky Facilities – as well as associated expansion plans at these locations – remain in place.
As a result of this action, Riot is reducing its previously announced total self-mining hash rate capacity growth and associated capital expenditures for 2025 and will provide additional updates as this review process progresses further.
&nbsp;

RIOT

Riot Platforms Halts Previously Announced Phase II Bitcoin Mining Expansion At Corsicana Facility; Now Projects Capital Expenditures At The Facility In 2025 To Be Reduced By $245M

Comments

Broncus Holding

News

Latest news for Broncus Holding (OTC:BRNHF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga